RENB
NASDAQ
Lunai Bioworks Inc. - Common Stock
Healthcare
· Biotechnology
$0.37
▼ $-0.04
(-9.47%)
Vol 1.1M
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$32.9M
ROE
-67.2%
D/E
6.77
Beta
-3.54
52W
$1–$21
Price Chart
Fundamentals Trend
| Metric | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-09-02 | 2025-10-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -82.5% | -104.6% | -98.5% | -67.2% | -67.2% | -67.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 1.86 | 2.66 | 6.25 | 6.77 | 6.77 | 6.77 |
| Current Ratio | 0.07 | 0.08 | 0.06 | 0.13 | 0.13 | 0.13 |
Key Ratios
ROA (TTM)
-52.4%
P/B
1.7
EPS (TTM)
$-0.43
CF/Share
$-0.70
52W High
$21.00
52W Low
$1.13
$1.13
52-Week Range
$21.00
How does RENB compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
RENB valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
1.7
▼
29%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
RENB profitability vs Biotechnology peers
ROE
-67.2%
▲
0%
above
peers
(-67.3%)
vs Peers
vs Industry
In line
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-52.4%
▼
12%
below
peers
(-46.7%)
vs Peers
vs Industry
In line
RENB financial health vs Biotechnology peers
D/E ratio
6.8
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
0.1
▼
97%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
-3.5
▼
465%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
RENB fundamentals radar
RENB
Peer median
Industry
RENB profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio